Adagene

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Earnings data Q4 2020

SAN FRANCISCO and SUZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced updated preclinical data from its lead SAFEbody™ program, ADG126, are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.

Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021

- Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds- -Reported clinical data for anti-CD137 and two anti-CTLA-4 programs- -Advanced five discovery programs into IND-enabling stage- -Established multiple academic and industry partnerships- -Further strengthened Executive Management team-

Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates

-NEObody™ product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial-  -Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism- -Poised for global expansion-

Adagene Announces Clinical Advancement for ADG116

SAFEbody technology enables precision masking of antibodies for enhanced safety SAFEbody technology enables precision masking of antibodies for enhanced safety

Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program

Baosheng Media Group Holdings

Bumble

Bioventus

Decibel Therapeautics

Viant Technology

Longeveron

NexImmune

Cloopen Group Holding

Global Internet of People

Signify Health

Urban-gro

Vallon Pharmaceuticals

The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble, which completed the year's largest deal so far, and Chinese cloud services provider Cloopen Group, which bagged the biggest pop of 2021 to date.

U.S. IPO Weekly Recap: IPO Frenzy Brings The Year's Largest Deal And Biggest Pop In A 17 IPO Week

I-Mab

Eli Lilly

Morphosys AG - ADR

Adagene completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Nuance Pharma in-licensed Greater China rights to a late-stage candidate for osteoarthritis pain from Antibe Therapeutics in a $100 million agreement.

Week In Review: Suzhou's Adagen Raises $140 Million In U.S. IPO To Develop Oncology Drugs

SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies, today announced the closing of its initial public offering (the "IPO") of 8,457,100 American depositary shares ("ADSs"), at public offering price of US$19.00 per ADS. The number of ADSs issued at closing included the exercise in full of the underwriters' option to purchase 1,103,100 additional ADSs from the Company. The aggregate gross proceeds from the IPO were approximately US$161 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. Each ADS represents one and one quarter (1.25) ordinary shares of the Company. The ADSs began trading on the Nasdaq Global Market on February 9, 2021 under the ticker symbol "ADAG."

Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option

SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies, today announced that it has priced its initial public offering (the "IPO") of 7,354,000 American depositary shares ("ADSs"), at US$19.00 per ADS. The aggregate offering size of the IPO is approximately US$140.0 million, assuming the underwriters do not exercise their over-allotment option to purchase any additional ADSs. Each ADS represents one and one quarter (1.25) ordinary shares of the Company. The ADSs are expected to begin trading on the Nasdaq Global Market on February 9, 2021 under the ticker symbol "ADAG." The IPO is expected to close on February 11, 2021, subject to customary closing conditions.

News for Adagene Stock (ADAG)